HNL News

December 06, 2022

Oncomine Myeloid Assay Coming Soon!

Myeloid malignancies are clonal diseases with multiple known genetic mutations. Genomic sequencing is advantageous in the classification and treatment of these diseases and can now be performed with a single test.

Read More
November 18, 2022

RSV Surge Continues, Putting Infants at Risk

Cases of RSV, or respiratory syncytial virus, are surging in the United States at rates far higher and earlier than expected. RSV-associated hospitalizations have more than doubled compared to last season¹. Download RSV| The Surge Continues, Putting Infants at Risk Infographic
Read More
November 17, 2022

A Day in the Life of an HNL Lab Medicine Courier

Are you curious about what a day in the life of an HNL Lab Medicine Courier is like?   
Read More
November 14, 2022

November is Lung Cancer Awareness Month

Lung cancer is responsible for the highest number of cancer deaths with an estimated 130,180 deaths each year¹.

Read More
November 10, 2022

World Diabetes Day

Over 34 million Americans have diabetes, there is a good chance that you or someone you know is living with diabetes¹. But what about people who don’t know?
Read More
HNL News

October 28, 2022

B-cell lymphoma is a large group of heterogenous disorders and comprises a majority of non-Hodgkin lymphomas. As a poor survival rate characterizes these aggressive lymphomas, early detection and treatment is vital. Fluorescence in situ hybridization (FISH) is a sensitive method to detect smaller genomic changes associated with various hematological malignancies and solid tumors. The high sensitivity of FISH analysis detects low-level clones and identifies prognostically and therapeutically important genetic abnormalities. This new in-house panel delivers prompt results and complements HNL Genomics offerings.

Information

The non-Hodgkin lymphoma FISH panel detects IGH gene translocations or rearrangements involving the 14q32 locus. Included in this group are follicular lymphoma (FL), Burkitt Lymphoma (BL), and diffuse large B-cell lymphoma (DLBCL). The characteristic chromosome abnormality t(14;18) resulting in IGH/BCL2 fusion is seen in about 80% of FL and about 20-30% of DLBCL. A majority of patients with BL harbor the characteristic t(8;14), resulting in c-MYC/IGH fusion. BCL6 gene rearrangements are also associated with B-cell lymphoma. Cyclin D1 gene rearrangements, especially the t(11;14), distinguish mantle cell lymphoma (ML) from other lymphoproliferative disorders, hence are diagnostic for ML.

Benefits

There are several advantages of FISH technology over routine chromosome analysis, including the ability of FISH technology to detect genomic abnormalities in non-viable and non-dividing tissues, rapid turnaround time, and increased resolution. However, FISH technology is complementary to routine chromosome analysis and cannot substitute routine chromosome analysis for the diagnosis of cancer.
Providers suspecting non-Hodgkin lymphoma can order this panel easily using the test code FPNHL. Our genetic testing experts are available to assist with any questions. The average turnaround time for our non-Hodgkin lymphoma FISH panel is 3-4 days. Results are available in EPIC.

Test Summary

  • Non-Hodgkin lymphoma FISH panel
  • Detects most common abnormalities related to Non-Hodgkins Lymphoma (NHL) by chromosome analysis and FISH testing.
  • Test Code FPNHL
  • Turnaround time: 3-4 days

Time matters to your patients. HNL Lab Medicine delivers patient results quickly and conveniently. Please take advantage of our newly available non-Hodgkin lymphoma FISH panel to provide superior patient care.

For questions or assistance, please call 877-402-4221. For technical questions related to this test, please ask for Technical Support between the hours of 8 a.m. to 4:30 p.m. For general inquiries, Customer Care is available to assist at any time.

Following are the probes included in the NHL panel.
ALK, BCL6, MYC, MYC/IGH, IGH, IGH/BCL2, BCL2, CCND1/IGH, MALT1